Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles

Venishetty, Vinay Kumar; Komuravelli, Rojarani; Kuncha, Madhusudana; Sistla, Ramakrishna; Diwan, Prakash V.

doi:10.1016/j.nano.2012.03.003

Cited by 80 publications

(53 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TAT PTX/TOS-CDDP SLNs were prepared using emulsification and solvent evaporation method ( Figure 2). 27 Briefly, PTX (20 mg), TOS-CDDP (10 mg), SLB (50 mg), and GMS (100 mg) were dissolved in chloroform (5 mL) to produce an oil phase. TAT-PEG-DSPE and Tween 80 (1%) were dissolved in double distilled water (45 mL) to form aqueous phase.…”

Section: Synthesis and Characterization Of Tat-peg-dspementioning

confidence: 99%

“…[27][28][29] They display distinctive features such as high drug loading, capability for modifications and conjugations, and so forth. [27][28][29] Solid lipid nanoparticles (SLNs) were established as alternative lipidbased nanocarriers such as emulsions, micelles, liposomes, and polymeric NPs. SLNs are composed of 0.1%-30% (w/w) lipids dispersed in an aqueous solution of 0.5%-5.0% (w/w) surfactant as stabilizing agent.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer

Liu¹,

Liang²,

Liu³

et al. 2017

IJN

103

View full text Add to dashboard Cite

Background Cervical cancer is a major world health problem for women. Currently, cancer research focuses on improving therapy for cervical cancer using various treatment options such as co-delivery of chemotherapeutic agents by nanocarriers. Purpose The aim of this study was to develop trans-activating transcriptional activator (TAT)-modified solid lipid nanoparticles (SLNs) for co-delivery of paclitaxel (PTX) and α-tocopherol succinate-cisplatin prodrug (TOS-CDDP) (TAT PTX/TOS-CDDP SLNs) in order to achieve synergistic antitumor activity against cervical cancer. Methods Lipid prodrug of CDDP (TOS-CDDP) and TAT-containing polyethylene glycol-distearoyl-phosphatidylethanolamine (TAT-PEG-DSPE) were synthesized. TAT PTX/TOS-CDDP SLNs were prepared by emulsification and solvent evaporation method. Physicochemical characteristics of SLNs such as size, morphology, and release profiles were explored. In vitro and in vivo studies were carried out to assess the efficacy of their antitumor activity in target cells. Results TAT PTX/TOS-CDDP SLNs could be successfully internalized by HeLa cells and showed a synergistic effect in the suppression of cervical tumor cell growth. They exhibited high tumor tissue accumulation, superior antitumor efficiency, and much lower toxicity in vivo. Conclusion The present study indicates that the co-delivery system provides a promising platform as a combination therapy for the treatment of cervical cancer, and possibly other types of cancer as well.

show abstract

Section: Synthesis and Characterization Of Tat-peg-dspementioning

confidence: 99%

mentioning

confidence: 99%

Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer

Liu¹,

Liang²,

Liu³

et al. 2017

IJN

103

View full text Add to dashboard Cite

show abstract

“…Hence, it was hypothesized that first release of curcumin could inhibit p-gp and increase the cellular uptake of paclitaxel. A few studies have reported to overcome p-gp and enhance cytotoxicity by co-administration of a p-gp inhibitor with anticancer drug [20, 30]. Besides, both of drugs could show synergistic effect because curcumin and paclitaxel have different cytotoxic mechanisms.…”

Section: Discussionmentioning

confidence: 99%

A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells

Baek

Cho

2017

Oncotarget

View full text Add to dashboard Cite

The objective of the work was to develop a multifunctional nanomedicine based on a folate-conjugated lipid nanoparticles loaded with paclitaxel and curcumin. The novel system combines therapeutic advantageous of efficient targeted delivery via folate and timed-release of curcumin and paclitaxel via 2-hydroxypropyl-ß-cyclodextrin, thereby overcoming multidrug resistance in breast cancer cells (MCF-7/ADR). The faster release of curcumin from the folate-conjugated curcumin and paclitaxel-loaded lipid nanoparticles enables sufficient p-glycoprotein inhibition, which allows increased cellular uptake and cytotoxicity of paclitaxel. In western blot assay, curcumin can efficiently inhibit the expression of p-glycoprotein, conformed the enhancement of cytotoxicity by paclitaxel. Furthermore, folate-conjugated curcumin and paclitaxel-loaded lipid nanoparticles exhibited increased uptake of paclitaxel and curcumin into MCF-7/ADR cells through the folate receptor-mediated internalization. Taken together, these results indicate that folate-conjugated curcumin and paclitaxel-loaded lipid nanoparticles enables the enhanced, folate-targeted delivery of multiple anticancer drugs by inhibiting the multi-drug resistance efficiently, which may also serve as a useful nano-system for co-delivery of other anticancer drugs.

show abstract

“…P-glycoprotein efflux at the brain limits entry of Docetaxel for cancer treatment. Folic acid modified solid lipid nanoparticles loaded with docetaxel and ketoconazole (P-gp inhibitor) evaluated in brain endothelial cell lines for cytotoxicity and cell uptake revealed a brain permeation coefficient 44 times higher than that of Taxotere ® (Venishetty et al, 2013). Docetaxel loaded hepatoma-targeted SLNs revealed high cellular uptake by hepatoma cells, better biodistribution and enhanced antitumor efficacy due to increased drug accumulation and cytotoxicity in murine model bearing hepatoma and hepatocellular carcinoma cell line BEL7402 compared to Taxotere ® or non-targeted SLNs for treatment of advanced and metastatic hepatocellular carcinoma (Xu et al, 2009).…”

Section: Nanocarriers As Potential Drug Delivery Systems In Cancer Thmentioning

confidence: 99%

Nanodrug delivery in reversing multidrug resistance in cancer cells

et al. 2014

View full text Add to dashboard Cite

Different mechanisms in cancer cells become resistant to one or more chemotherapeutics is known as multidrug resistance (MDR) which hinders chemotherapy efficacy. Potential factors for MDR includes enhanced drug detoxification, decreased drug uptake, increased intracellular nucleophiles levels, enhanced repair of drug induced DNA damage, overexpression of drug transporter such as P-glycoprotein(P-gp), multidrug resistance-associated proteins (MRP1, MRP2), and breast cancer resistance protein (BCRP). Currently nanoassemblies such as polymeric/solid lipid/inorganic/metal nanoparticles, quantum dots, dendrimers, liposomes, micelles has emerged as an innovative, effective, and promising platforms for treatment of drug resistant cancer cells. Nanocarriers have potential to improve drug therapeutic index, ability for multifunctionality, divert ABC-transporter mediated drug efflux mechanism and selective targeting to tumor cells, cancer stem cells, tumor initiating cells, or cancer microenvironment. Selective nanocarrier targeting to tumor overcomes dose-limiting side effects, lack of selectivity, tissue toxicity, limited drug access to tumor tissues, high drug doses, and emergence of multiple drug resistance with conventional or combination chemotherapy. Current review highlights various nanodrug delivery systems to overcome mechanism of MDR by neutralizing, evading, or exploiting the drug efflux pumps and those independent of drug efflux pump mechanism by silencing Bcl-2 and HIF1α gene expressions by siRNA and miRNA, modulating ceramide levels and targeting NF-κB. “Theragnostics” combining a cytotoxic agent, targeting moiety, chemosensitizing agent, and diagnostic imaging aid are highlighted as effective and innovative systems for tumor localization and overcoming MDR. Physical approaches such as combination of drug with thermal/ultrasound/photodynamic therapies to overcome MDR are focused. The review focuses on newer drug delivery systems developed to overcome MDR in cancer cell.

show abstract

Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles

Cited by 80 publications

References 22 publications

Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer

Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer

A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells

Nanodrug delivery in reversing multidrug resistance in cancer cells

Contact Info

Product

Resources

About